NCT00814333

Trial Comparing Outcomes With Merocel Packing or Thrombin-JMI for Anterior Epistaxis

A Randomized Controlled Trial Comparing Outcomes in Patients Treated With Merocel Packing or Thrombin-JMI for Anterior Epistaxis

• Status: Terminated
• Phase: N/A
• Study type: Interventional
• Enrollment: 1 (actual)
• Sponsor: University of Kansas Medical Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Epistaxis is a common problem among people of all ages and backgrounds. However, occasionally epistaxis can be severe enough to require emergency room admission. Among the treatment options for epistaxis, nasal packing is the most common approach. This approach requires a return visit to the clinic for removal of the packing. Additionally, there is a great deal of pain during the insertion and removal of this packing. This study aims to justify the further investigation of thrombin as a potential treatment approach for these patients. Thrombin could provide a treatment approach that reduces pain and eliminates the need for a return visit to the clinic.

Conditions

• Epistaxis

Interventions

Type	Name	Description
DRUG	Thrombin-JMI	5,000 IU, to nasal mucosa via syringe spray applicator
DRUG	Merocel pack	8 cm pack, inserted within the affected side between the septum and inferior turbinate via bayonet forceps

Timeline

• Start date: 2008-12-01
• Primary completion: 2011-08-01
• Completion: 2011-08-01
• First posted: 2008-12-24
• Last updated: 2016-01-15
• Results posted: 2016-01-15

Locations

1 site across 1 country: United States